Hutz, Janna, Nelson, Thomas, Wu, Hua, Mcallister, Gregory, Moutsatsos, Ioannis, Jaeger, Savina, Bandyopadhyay, Somnath, Nigsch, Florian, Cornett, Allen, Jenkins, Jeremy and Selinger, Douglas (2013) The multidimensional perturbation value: A single metric to measure similarity and activity of treatments in high-throughput multidimensional screens. Journal of Biomolecular Screening, 18 (4). pp. 367-377. ISSN 1087-0571; 1552-454X

Abstract

Screens using high-throughput, information-rich technologies such as microarrays, high-content screening (HCS), and next-generation sequencing (NGS) have become increasingly widespread. Compared with single-readout assays, these methods produce a more comprehensive picture of the effects of screened treatments. However, interpreting such multidimensional readouts is challenging. Univariate statistics such as t-tests and Z-factors cannot easily be applied to multidimensional profiles, leaving no obvious way to answer common screening questions such as "Is treatment X active in this assay?" and "Is treatment X different from (or equivalent to) treatment Y?" We have developed a simple, straightforward metric, the multidimensional perturbation value (mp-value), which can be used to answer these questions. Here, we demonstrate application of the mp-value to three data sets: a multiplexed gene expression screen of compounds and genomic reagents, a microarray-based gene expression screen of compounds, and an HCS compound screen. In all data sets, active treatments were successfully identified using the mp-value, and simulations and follow-up analyses supported the mp-value's statistical and biological validity. We believe the mp-value represents a promising way to simplify the analysis of multidimensional data while taking full advantage of its richness. © 2012 Society for Laboratory Automation and Screening.

Item Type:	Article
Additional Information:	Unmapped bibliographic data: LA - English [Field not mapped to EPrints] ST - The multidimensional perturbation value: A single metric to measure similarity and activity of treatments in high-throughput multidimensional screens [Field not mapped to EPrints] AU - Hutz, J. E. [Field not mapped to EPrints] AU - Nelson, T. [Field not mapped to EPrints] AU - Wu, H. [Field not mapped to EPrints] AU - McAllister, G. [Field not mapped to EPrints] AU - Moutsatsos, I. [Field not mapped to EPrints] AU - Jaeger, S. A. [Field not mapped to EPrints] AU - Bandyopadhyay, S. [Field not mapped to EPrints] AU - Nigsch, F. [Field not mapped to EPrints] AU - Cornett, B. [Field not mapped to EPrints] AU - Jenkins, J. L. [Field not mapped to EPrints] AU - Selinger, D. W. [Field not mapped to EPrints] AD - (Hutz, Nelson, Wu, McAllister, Moutsatsos, Jaeger, Cornett, Jenkins, Selinger) Developmental and Molecular Pathways, Novartis Institutes for Biomedical Research, 250 Massachusetts Ave., Cambridge, MA 02139, United States [Field not mapped to EPrints] DB - Embase [Field not mapped to EPrints] DP - Ovid Technologies [Field not mapped to EPrints] AN - 2013213324 [Field not mapped to EPrints]
Keywords:	high-content screening
Date Deposited:	01 Feb 2017 00:45
Last Modified:	01 Feb 2017 00:45
URI:	https://oak.novartis.com/id/eprint/7566